Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Cristiano Ferrario, Ronald de Wit et al.|The Lancet|2017Cited by 177
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD. Ross Camidge, Shun Lü, Alona Zer et al.|Journal of Clinical Oncology|2024Cited by 131
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis Paz‐Ares, C. Chouaïd, Óscar Juan et al.|Journal of Clinical Oncology|2024Cited by 126
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Siobhan Ng, Ronald de Wit et al.|The Lancet Oncology|2019Cited by 87
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung CancerLauren A. Byers, Martin Förster, Alejandro Navarro et al.|Clinical Lung Cancer|2021Cited by 39